Latest Breaking News On - Eric zi - Page 1 : comparemela.com

VenusP-Valve granted IDE approval for clinical trial, unveiling a new chapter for Chinese valve solutions globally

Recently, Venus Medtech (Hangzhou) Inc. ("Venus Medtech"), a leading provider of integrated solutions for transcatheter structural heart valvular therapies in China, announced the Investigational Device Exemption (IDE) full approval for its in-house developed VenusP-Valve from the U.S. Food and Drug Administration (FDA). VenusP-Valve, thus, has become the first China-developed heart valvular system to be approved by the FDA for clinical trial, setting a new milestone in the global footprint of C

United kingdomEric ziVenus medtechVenus medtech hangzhou incPre market approvalMedical devices regulationExecutive directorGeneral manager

Venus Medtech (Hangzhou) Inc : VenusP-Valve granted IDE approval for clinical trial, unveiling a new chapter for Chinese valve solutions globally

Venus Medtech (Hangzhou) Inc : VenusP-Valve granted IDE approval for clinical trial, unveiling a new chapter for Chinese valve solutions globally
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomEric ziVenus medtechDrug administrationVenus medtech hangzhou incInvestigational device exemptionPre market approvalMedical devices regulationExecutive directorGeneral managerAktien sie

Confirmatory clinical trial of Liwen RF™ ablation system in China concluded

/PRNewswire/ On March 3, Venus Medtech (Hangzhou) Inc. (Venus Medtech, 2500.HK), trailblazer in structural heart therapies worldwide, announced that the.

Mao chenUnited statesYun zhangEric ziLiwen liuVenus medtechVenus medtech hangzhou incXiamen cardiovascular hospital universitySichuan universityQilu hospital of shandong universityFudan universityUniversity of healthHangzhou nuocheng medical technology co ltdFirst affiliated hospital of dalian medical universityNational medical products administrationZhejiang university school of medicine

Venus Medtech (Hangzhou) Inc : Confirmatory clinical trial of Liwen RF ablation system in China concluded

HANGZHOU, China, March 4, 2023 /PRNewswire/ On March 3, Venus Medtech (Hangzhou) Inc. (Venus Medtech, 2500.HK), trailblazer in structural heart therapies worldwide, announced that the Liwen

Mao chenUnited statesYun zhangDennis riedlEric ziLiwen liuVenus medtechVenus medtech hangzhou incXiamen cardiovascular hospital universitySichuan universityQilu hospital of shandong universityFudan universityUniversity of healthHangzhou nuocheng medical technology co ltdFirst affiliated hospital of dalian medical universityNational medical products administration

Venus Medtech (Hangzhou) Inc : Venus Medtech announces 2022 interim results: quality and efficiency improvement, profitability focus, rapid progress in global presence

HANGZHOU, China, Sept. 1, 2022 /PRNewswire/ On August 31, 2022, Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter referred to as "Venus Medtech"), a leading provider of integrated solutions

United statesEric ziKostenloser wertpapierhandelVenus medtechAcquisition of cardiovalve ltdVenus medtech hangzhou incNational medical products administrationInvestigator meetingBreakthrough device designationApproval proceduresInnovative medical devicesExecutive directorGeneral manager